Peng Dai
VP & Head of FinanceMr. Peng Dai is Vice President & Head of Finance of InSilico Medicine Cayman TopCo from November 2023. Mr. Dai joined the InSilico Medicine Cayman TopCo in June 2021. He first joined Company as a director in financial planning and analysis in June 2021 and served as a senior director from September 2022 to October 2023. Mr. Dai served successively as a director in the finance department at WuXi AppTec (Shanghai) Co., Ltd., a wholly-owned subsidiary of WuXi AppTec Co., Ltd., a company listed on the Stock Exchange (HKEx: 2359) and the Shanghai Stock Exchange (SSE: 603259), from August 2017 to May 2021, where he was responsible for providing financial analysis and advices on business operations of the company. Prior to joining WuXi AppTec (Shanghai) Co., Ltd., Mr. Dai served successively as a senior finance planning analyst at Thermo Fisher Scientific (China) Co., Ltd. from June 2013 to August 2017. Mr. Dai also worked as a senior auditor at Deloitte Touche Tohmatsu Certified Public Accountants LLP from September 2010 to April 2013, where he led a number of audit projects. Mr. Dai received his bachelor’s degree in commerce (accounting and corporate finance) from the University of Adelaide in Australia in August 2009 and his master’s degree in commerce (applied finance) from the University of Adelaide in Australia in July 2010. Mr. Dai has been awarded Deloitte Green Dot Award in November 2012, WuXi AppTec Group A+ Employee in 2017, 2018 and 2019 and he is also a member of Certified Practising Accountant Australia.
Positions
- Company NameInSilico Medicine Cayman TopCoStock Code03696PositionVP & Head of FinanceColleagues
- AZAleksandrs ZhavoronkovFounder, CEO, Chief Business Officer, Longevity Board Member & Chairman of the Board
- FRFeng RenCO-CEO, Chief Scientific Officer, Longevity Board Member & Executive Director
- AAAleksandr AliperPresident
- XDXiao DingHead of Chemistry
- JWJingsong WangIndependent Non-Executive Director
- RKRoman KyrychynskyiIndependent Non-Executive Director
- AAAndrew AdamsChairman of Longevity Board
